TIDMNCYT
Novacyt S.A.
12 June 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Reminder to shareholders re. AGM voting
Paris, France and Eastleigh, UK - 12 June 2023 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, will be holding its annual general meeting
(AGM) exclusively as an open online meeting at 1pm BST/2pm CEST on
Thursday, 15 June 2023. As usual, and in accordance with French
corporate law, the AGM comprises both ordinary and extraordinary
resolutions. All materials can be found at
www.novacyt.com/investors .
The Board would like to strongly encourage shareholders to
submit their votes in advance, in accordance with the instructions
in the Notice of the AGM.
U nder French law, for the AGM and EGM meetings to be quorate at
the first attempt, shareholders representing at least 20% of the
share capital and voting rights, on ordinary resolutions, and 25%
of the share capital and voting rights, on extraordinary
resolutions, must be present, represented or have voted in advance
under the conditions set out below.
Shareholders can vote in advance of the AGM by:
-- Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors , completing it and returning it together
with evidence of their shareholding which must be in the form of a
share certificate (attestation), either by post to the following
address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to
the following address: serviceproxy@cic.fr , or
investor.relations@novacyt.com , no later than 12 June 2023
inclusive.
-- Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu if securities held on
Euronext Growth are registered with any of the following banks:
CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP
Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital,
Citibank, Deutsche Bank, Bank of New York or JP Morgan. The
Votaccess portal will be open from 26 May 2023 to 14 June 2023 2pm
BST/3pm CEST.
-- Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves
Lansdown are now using the Broadridge ProxyVote on-line voting
portal.
Shareholders can register for the AGM and access the online
meeting by visiting www.novacytagm23.eventcaster.co.uk .
Registrations must be accompanied by formal evidence of
shareholding.
Following registration approval, shareholders will be able to
virtually attend the AGM and vote online during the meeting if they
wish, providing formal evidence of holding has been provided prior
to the meeting.
Shareholders who have already voted (through a proxy, via their
broker, nominee, bank, authorised intermediary , Votaccess portal
or Broadridge ProxyVote) will be allowed to attend the AGM but will
not be able to vote twice.
Following the meeting, a recording of the AGM will be available
on the Company's website at www.novacyt.com/investors .
Contacts
Novacyt SA +44 (0) 20 7756 1300
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
SP Angel Corporate Finance LLP (Nominated
Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Jack
McLaren
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Paul McManus / Stephanie Cuthbert novacyt@walbrookpr.com
/ Anna Dunphy
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
Novacyt is headquartered in Vélizy in France with offices in
Stokesley and Eastleigh, UK, and is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUASVROBUNAAR
(END) Dow Jones Newswires
June 12, 2023 02:00 ET (06:00 GMT)
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
